ILMN — Illumina Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $207.01
- YTD price return
- +57.83%
- YTD total return
- +57.83%
- Market cap
- 31.3B
- Enterprise value
- 32.3B
- Shares outstanding
- 151.2M
- 52W low
- $112.65
- 52W high
- $309.35
- From 52W high
- -33.08%
- From 52W low
- +83.76%
- 52W range
- 48%$113–$309
- Beta
- 1.45
Volume
- Rel volume
- 0.51×
- 30D volume
- 2.4M
- 30D $ vol
- 612.8M
Insider trading
- Insider net 1W
- −$61.2M
- Insider net 1M
- −$127.7M
- Insider net 3M
- −$415.9M
- Insider net 1Y
- −$720.4M
Form 4 transactions by trade date, as filed; latest on file 2026-11-11.
Fundamentals
- Sales (ttm)
- 4.5B
- Sales/share
- $30.01
- EPS (ttm)
- $5.83
- FCF (ttm)
- 1.1B
- FCF/share
- $6.99
- Book value/share
- $20.80
- Net margin
- 19.72%
- ROE
- 28.46%
- ROA
- 13.14%
- Debt / equity
- 0.57×
- Current ratio
- 2.63
Growth (CAGR, ttm) · 10Y
- Sales
- +5.85%+0.54%+1.18%+6.72%
- Net income
- +27.60%n/a-0.24%+7.29%
- FCF
- +5.72%+84.63%+17.71%+6.88%
- Shares
- -1.05%-1.63%-0.66%+0.29%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +30.73%n/a-0.87%+6.92%
- Sales/share
- +6.97%+2.21%+1.86%+6.41%
- FCF/share
- +6.84%+87.69%+18.50%+6.58%
- Book value/share
- +33.62%-17.63%-21.11%+3.16%
- Price
- +72.67%+31.87%-11.11%+4.45%
- Total return
- +72.67%+31.87%-11.11%+4.45%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 35.5×
- P/OI (ttm)
- 32.6×
- Fwd P/E
- 34.4×
- P/S (ttm)
- 6.9×
- P/B (mrq)
- 10.0×
- P/FCF (ttm)
- 29.6×
- EV/EBITDA (fy)
- 26.1×
- EV/Sales (ttm)
- 7.1×
- FCF yield (ttm)
- 3.38%
- Buyback yield (realized, 1y)
- 1.05%
- Shareholder yield (realized, 1y)
- 1.05%
- Buyback yield (cash, ttm)
- 1.20%
- Shareholder yield (cash, ttm)
- 1.20%
Vs own 10Y history
- P/E
- 20th
- P/OI
- 19th
- P/S
- 37th
- P/B
- 54th
- P/FCF
- 15th
Bar = where today’s multiple sits in ILMN’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-13#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y CAGR +6.8%10Y CAGR +2.8%YoY +34.4%EPS (diluted)
5Y CAGR +4.1%10Y CAGR +5.8%YoY +45.9%Free cash flow
5Y CAGR +0.9%10Y CAGR +3.8%YoY +49.8%TTM: operating cash flow $1.2B, capex −$173M
Q3 2026: operating cash flow $419M, capex −$40M
Shares (diluted)
5Y +5.4%10Y +4.7%YoY +0.0%Net income
5Y CAGR +5.3%10Y CAGR +6.3%YoY +46.7%About Illumina#
Data provided bySource: Twelve DataIllumina Inc. is a global genomics and life sciences company that develops DNA sequencing and array-based technologies used to analyze genetic variation and biological function. Its products and systems support research, clinical testing, and applied markets across areas such as oncology, inherited and infectious diseases, reproductive health, and molecular diagnostics. Illumina also provides sequencing consumables, instruments, software, and support services that help laboratories generate, interpret, and manage genomic data. The company serves customers including academic institutions, genomic research centers, hospitals, pharmaceutical and biotechnology companies, and clinical laboratories. Headquartered in San Diego, California, and founded in 1998, Illumina plays a central role in making genomic analysis more widely accessible for research and healthcare applications.
San Diego, CA·8,600 employees·Diagnostics & Research·illumina.com·As of Oct 28, 2026
Recent filings#
- Nov 11Insider sale · Meister Keith A. (Director) sold 2,621,726 shares for $563.8M on 16 days since Aug 4
- Oct 29Earnings · Earnings release — EPS $1.44 vs $1.36 est. (+5.9%); revenue $1.13B (+4% y/y) 18.6%
- Jul 30Earnings · Earnings release — EPS $1.31 vs $1.23 est. (+6.5%); revenue $1.16B (+9% y/y) 0.0%
ETFs holding ILMN#
25 of the 193 ETFs ChartRow carries live hold ILMN. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IBB | iShares Biotechnology ETF | 2.1% |
| ARKK | ARK Innovation ETF | 1.5% |
| IJH | iShares Core S&P Mid-Cap ETF | 0.7% |
| MDY | SPDR S&P MidCap 400 ETF Trust | 0.7% |
| VHT | Vanguard Health Care ETF | 0.4% |
| VBK | Vanguard Small-Cap Growth ETF | 0.4% |
| VXF | Vanguard Extended Market ETF | 0.3% |
| VB | Vanguard Small-Cap ETF | 0.3% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +23.75% | +1.14% |
| JNJ | Johnson & Johnson | +14.94% | +0.79% |
| ABBV | AbbVie Inc. | +7.53% | +0.20% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +7.86% | +0.58% |
| MRK | Merck & Co. Inc. | +4.07% | +0.55% |
| NVS | Novartis AG | +12.70% | +0.16% |
| TMO | Thermo Fisher Scientific Inc. | +5.61% | +0.11% |
| AMGN | Amgen Inc. | +12.80% | -0.30% |
